Evidence map›Paper›PMID 31979229›Full record

ArticleCancers2020

Reply to Comment on "Malfitano, A.M. et al. Virotherapy as a Potential Therapeutic Approach for the Treatment of Aggressive Thyroid Cancer"

Anna Maria Malfitano, Sarah Di Somma, Nella Prevete, Giuseppe Portella

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Anna Maria MalfitanoDipartimento di Scienze Mediche Traslazionali, Università Federico II Napoli, URT "Genomic of Diabetes" of Institute of Experimental Endocrinology and Oncology "G. Salvatore", National Council of Research (CNR), 80131 Naples, Italy.
Sarah Di SommaDipartimento di Scienze Mediche Traslazionali, Università Federico II Napoli, URT "Genomic of Diabetes" of Institute of Experimental Endocrinology and Oncology "G. Salvatore", National Council of Research (CNR), 80131 Naples, Italy.
Nella PreveteDipartimento di Scienze Mediche Traslazionali, Università Federico II Napoli, URT "Genomic of Diabetes" of Institute of Experimental Endocrinology and Oncology "G. Salvatore", National Council of Research (CNR), 80131 Naples, Italy.
Giuseppe PortellaDipartimento di Scienze Mediche Traslazionali, Università Federico II Napoli, URT "Genomic of Diabetes" of Institute of Experimental Endocrinology and Oncology "G. Salvatore", National Council of Research (CNR), 80131 Naples, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Our work is focused on the future clinical use of oncolytic viruses (OVs) for the treatment of aggressive thyroid carcinomas. Therefore, we provide a brief description of the overall use of OVs in the clinic. Rigvir is among the few OVs that have already been used for the treatment of patients, and studies describing its effects have been briefly commented and cited in our text [1]. [...].

Identifiers

PMID31979229
PMCPMC7073196

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.